Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

278
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
278
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

12.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
12.0K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

286
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
286
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

311
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
311

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comment on "Intravenous Versus Inhaled Milrinone in Patients with Known Pulmonary Hypertension Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis".

Annals of cardiac anaesthesia·2026
Same author

Intravenous Versus Inhaled Milrinone in Patients with Known Pulmonary Hypertension Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis.

Annals of cardiac anaesthesia·2025
Same author

Hydroxocobalamin Versus Methylene Blue for Treatment of Vasoplegic Shock Following Cardiopulmonary Bypass: A Systematic Review and Meta-analysis.

Journal of cardiothoracic and vascular anesthesia·2024
Same author

The use of neurone specific enolase to prognosticate neurological recovery and long term neurological outcomes in OOHCA patients.

Journal of the Intensive Care Society·2023
Same author

Ondansetron for the Prevention of Pruritus in Women Undergoing Cesarean Delivery With Intrathecal Opioid: A Systematic Review and Meta-Analysis.

Anesthesia and analgesia·2023
Same author

The Transition From Ventilator to Video Call: The ICU Recovery Clinic.

Chest·2023

Related Experiment Video

Updated: Jan 14, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.4K

Recombinant Factor VIIa Versus Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: A Systematic

Matthew Cadd1, Daniel Puntis1, Sam Bullard2

  • 1Anaesthetic Department, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom.

Journal of Cardiothoracic and Vascular Anesthesia
|October 22, 2025
PubMed
Summary

Prothrombin complex concentrate (PCC) reduces chest tube output and thromboembolic events in cardiac surgery patients compared to recombinant factor VIIa (rFVIIa), without increasing acute kidney injury (AKI) or mortality.

Keywords:
acute kidney injurycardiac surgerycardiopulmonary bypasshemorrhageprothrombin complex concentraterecombinant factor 7athromboembolism

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.3K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.1K

Related Experiment Videos

Last Updated: Jan 14, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.4K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.3K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.1K

Area of Science:

  • Cardiovascular Surgery
  • Hematology
  • Critical Care Medicine

Background:

  • Perioperative hemorrhage is common in cardiac surgery, leading to increased morbidity and mortality.
  • Prothrombin complex concentrate (PCC) and recombinant factor VIIa (rFVIIa) are used to manage bleeding, but rFVIIa has raised concerns regarding acute kidney injury (AKI) and thromboembolic events.

Purpose of the Study:

  • To systematically review and meta-analyze the evidence comparing PCC and rFVIIa in adult cardiac surgery patients.
  • To evaluate the effects of PCC versus rFVIIa on chest tube output, adverse events, and mortality.

Main Methods:

  • Systematic review and meta-analysis of seven retrospective observational studies.
  • Inclusion of 962 adult patients undergoing cardiac surgery.

Main Results:

  • PCC significantly reduced total chest tube output (mean difference: -301.01 mL).
  • PCC was associated with reduced rates of thromboembolic disease (OR 0.55) and deep vein thrombosis (OR 0.28).
  • No significant differences were observed in AKI incidence or mortality between PCC and rFVIIa groups.

Conclusions:

  • PCC demonstrates a beneficial effect in reducing chest tube output and thromboembolic disease incidence.
  • PCC appears to be a safe alternative to rFVIIa in cardiac surgery, with no increased risk of AKI or mortality.